Nexus DX Raises $15M

San Diego-based Nexus DX, a stealth mode, biotech firm, has raised $9.0M in a venture round, according to a regulatory filing from the firm this week. Details on the funding have not been announced. Kleiner Perkins Caufield & Byers as well as Bay City Capital now have representatives on the board of directors of the firm. Nexus DX is headed by James Merselis, who has previously served at Alverix, HemoSense, Micronics, as well as Boehringer Mannheim Diagnostics. More information »